The estimated Net Worth of Sumi Shrishrimal is at least $3.13 Millón dollars as of 3 June 2024. Sumi Shrishrimal owns over 1,131 units of iRhythm Technologies Inc stock worth over $1,743,389 and over the last 3 years Sumi sold IRTC stock worth over $1,383,631.
Sumi has made over 7 trades of the iRhythm Technologies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Sumi sold 1,131 units of IRTC stock worth $100,557 on 3 June 2024.
The largest trade Sumi's ever made was selling 1,461 units of iRhythm Technologies Inc stock on 25 May 2021 worth over $518,348. On average, Sumi trades about 563 units every 111 days since 2021. As of 3 June 2024 Sumi still owns at least 23,298 units of iRhythm Technologies Inc stock.
You can see the complete history of Sumi Shrishrimal stock trades at the bottom of the page.
Sumi's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi y Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: